MyanmarTuberculosis profile
Population  2014 53 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 28 (20–37) 53 (38–70)
Mortality (HIV+TB only) 4.1 (3.3–5.1) 7.7 (6.1–9.5)
Prevalence  (includes HIV+TB) 240 (190–310) 457 (352–575)
Incidence  (includes HIV+TB) 200 (180–220) 369 (334–406)
Incidence (HIV+TB only) 19 (15–24) 36 (28–44)
         
Case detection, all forms (%) 70 (64–78)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 5 (3.1–6.8) 27 (15–39)
MDR-TB cases among notified pulmonary
TB cases
5 600 (3 500–7 700) 3 400 (1 900–4 900)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 42 608   5 276
Pulmonary, clinically diagnosed 70 305   3 650
Extrapulmonary 16 108   405
       
Total new and relapse 138 352    
Previously treated, excluding relapses 3 605    
Total cases notified 141 957    
Among 138 352 new and relapse cases:
36 301 (26%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 10 295 (24%) 15 166 (117%) 26 240
Laboratory-confirmed RR-/MDR-TB cases     3 495
Patients started on MDR-TB treatment ***     1 537
TB/HIV 2014 Number (%)
TB patients with known HIV status 56 133 (40)
HIV-positive TB patients 6 412 (11)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 4 666 (73)
HIV-positive TB patients on antiretroviral therapy (ART) 2 319 (36)
HIV-positive people screened for TB 54 178  
HIV-positive people provided with IPT 2 997  
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (87) 135 614
Previously treated cases registered in 2013 (71) 7 147
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (79) 443
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 38
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 36
% Funded domestically 11%
% Funded internationally 67%
% Unfunded 22%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-25 Data: www.who.int/tb/data